Cargando…

A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes: A randomized, controlled trial

OBJECTIVE: Insulin degludec/insulin aspart (IDegAsp) is a soluble coformulation of the novel basal analog insulin degludec (IDeg: 70%) and insulin aspart (IAsp: 30%). We compared the safety and efficacy of IDegAsp, an alternative formulation (AF) (55% IDeg and 45% IAsp), and insulin glargine (IGlar)...

Descripción completa

Detalles Bibliográficos
Autores principales: Heise, Tim, Tack, Cees J., Cuddihy, Robert, Davidson, Jaime, Gouet, Didier, Liebl, Andreas, Romero, Enrique, Mersebach, Henriette, Dykiel, Patrik, Jorde, Rolf
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041205/
https://www.ncbi.nlm.nih.gov/pubmed/21285389
http://dx.doi.org/10.2337/dc10-1905
_version_ 1782198418962120704
author Heise, Tim
Tack, Cees J.
Cuddihy, Robert
Davidson, Jaime
Gouet, Didier
Liebl, Andreas
Romero, Enrique
Mersebach, Henriette
Dykiel, Patrik
Jorde, Rolf
author_facet Heise, Tim
Tack, Cees J.
Cuddihy, Robert
Davidson, Jaime
Gouet, Didier
Liebl, Andreas
Romero, Enrique
Mersebach, Henriette
Dykiel, Patrik
Jorde, Rolf
author_sort Heise, Tim
collection PubMed
description OBJECTIVE: Insulin degludec/insulin aspart (IDegAsp) is a soluble coformulation of the novel basal analog insulin degludec (IDeg: 70%) and insulin aspart (IAsp: 30%). We compared the safety and efficacy of IDegAsp, an alternative formulation (AF) (55% IDeg and 45% IAsp), and insulin glargine (IGlar) in insulin-naïve subjects with type 2 diabetes inadequately controlled with oral antidiabetic drugs. RESEARCH DESIGN AND METHODS: In this 16-week, open-label trial, subjects (mean age 59.1 years, A1C 8.5%, BMI 30.3 kg/m(2)) were randomized to once-daily IDegAsp (n = 59), AF (n = 59), or IGlar (n = 60), all in combination with metformin. Insulin was administered before the evening meal and dose-titrated to a fasting plasma glucose (FPG) target of 4.0–6.0 mmol/L. RESULTS: After 16 weeks, mean A1C decreased in all groups to comparable levels (IDegAsp: 7.0%; AF: 7.2%; IGlar: 7.1%). A similar proportion of subjects achieved A1C <7.0% without confirmed hypoglycemia in the last 4 weeks of treatment (IDegAsp: 51%; AF: 47%; IGlar: 50%). Mean 2-h postdinner plasma glucose increase was lower for IDegAsp (0.13 mmol/L) and AF (0.24 mmol/L) than IGlar (1.63 mmol/L), whereas mean FPG was similar (IDegAsp: 6.8 mmol/L; AF: 7.4 mmol/L; IGlar: 7.0 mmol/L). Hypoglycemia rates were lower for IDegAsp and IGlar than AF (1.2, 0.7, and 2.4 events/patient year). Nocturnal hypoglycemic events occurred rarely for IDegAsp (1 event) and IGlar (3 events) compared with AF (27 events). CONCLUSIONS: In this proof-of-concept trial, once-daily IDegAsp was safe, well tolerated, and provided comparable overall glycemic control to IGlar at similar low rates of hypoglycemia, but better postdinner plasma glucose control.
format Text
id pubmed-3041205
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-30412052012-03-01 A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes: A randomized, controlled trial Heise, Tim Tack, Cees J. Cuddihy, Robert Davidson, Jaime Gouet, Didier Liebl, Andreas Romero, Enrique Mersebach, Henriette Dykiel, Patrik Jorde, Rolf Diabetes Care Original Research OBJECTIVE: Insulin degludec/insulin aspart (IDegAsp) is a soluble coformulation of the novel basal analog insulin degludec (IDeg: 70%) and insulin aspart (IAsp: 30%). We compared the safety and efficacy of IDegAsp, an alternative formulation (AF) (55% IDeg and 45% IAsp), and insulin glargine (IGlar) in insulin-naïve subjects with type 2 diabetes inadequately controlled with oral antidiabetic drugs. RESEARCH DESIGN AND METHODS: In this 16-week, open-label trial, subjects (mean age 59.1 years, A1C 8.5%, BMI 30.3 kg/m(2)) were randomized to once-daily IDegAsp (n = 59), AF (n = 59), or IGlar (n = 60), all in combination with metformin. Insulin was administered before the evening meal and dose-titrated to a fasting plasma glucose (FPG) target of 4.0–6.0 mmol/L. RESULTS: After 16 weeks, mean A1C decreased in all groups to comparable levels (IDegAsp: 7.0%; AF: 7.2%; IGlar: 7.1%). A similar proportion of subjects achieved A1C <7.0% without confirmed hypoglycemia in the last 4 weeks of treatment (IDegAsp: 51%; AF: 47%; IGlar: 50%). Mean 2-h postdinner plasma glucose increase was lower for IDegAsp (0.13 mmol/L) and AF (0.24 mmol/L) than IGlar (1.63 mmol/L), whereas mean FPG was similar (IDegAsp: 6.8 mmol/L; AF: 7.4 mmol/L; IGlar: 7.0 mmol/L). Hypoglycemia rates were lower for IDegAsp and IGlar than AF (1.2, 0.7, and 2.4 events/patient year). Nocturnal hypoglycemic events occurred rarely for IDegAsp (1 event) and IGlar (3 events) compared with AF (27 events). CONCLUSIONS: In this proof-of-concept trial, once-daily IDegAsp was safe, well tolerated, and provided comparable overall glycemic control to IGlar at similar low rates of hypoglycemia, but better postdinner plasma glucose control. American Diabetes Association 2011-03 2011-02-17 /pmc/articles/PMC3041205/ /pubmed/21285389 http://dx.doi.org/10.2337/dc10-1905 Text en © 2011 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
spellingShingle Original Research
Heise, Tim
Tack, Cees J.
Cuddihy, Robert
Davidson, Jaime
Gouet, Didier
Liebl, Andreas
Romero, Enrique
Mersebach, Henriette
Dykiel, Patrik
Jorde, Rolf
A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes: A randomized, controlled trial
title A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes: A randomized, controlled trial
title_full A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes: A randomized, controlled trial
title_fullStr A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes: A randomized, controlled trial
title_full_unstemmed A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes: A randomized, controlled trial
title_short A New-Generation Ultra-Long-Acting Basal Insulin With a Bolus Boost Compared With Insulin Glargine in Insulin-Naïve People With Type 2 Diabetes: A randomized, controlled trial
title_sort new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naïve people with type 2 diabetes: a randomized, controlled trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3041205/
https://www.ncbi.nlm.nih.gov/pubmed/21285389
http://dx.doi.org/10.2337/dc10-1905
work_keys_str_mv AT heisetim anewgenerationultralongactingbasalinsulinwithabolusboostcomparedwithinsulinglargineininsulinnaivepeoplewithtype2diabetesarandomizedcontrolledtrial
AT tackceesj anewgenerationultralongactingbasalinsulinwithabolusboostcomparedwithinsulinglargineininsulinnaivepeoplewithtype2diabetesarandomizedcontrolledtrial
AT cuddihyrobert anewgenerationultralongactingbasalinsulinwithabolusboostcomparedwithinsulinglargineininsulinnaivepeoplewithtype2diabetesarandomizedcontrolledtrial
AT davidsonjaime anewgenerationultralongactingbasalinsulinwithabolusboostcomparedwithinsulinglargineininsulinnaivepeoplewithtype2diabetesarandomizedcontrolledtrial
AT gouetdidier anewgenerationultralongactingbasalinsulinwithabolusboostcomparedwithinsulinglargineininsulinnaivepeoplewithtype2diabetesarandomizedcontrolledtrial
AT lieblandreas anewgenerationultralongactingbasalinsulinwithabolusboostcomparedwithinsulinglargineininsulinnaivepeoplewithtype2diabetesarandomizedcontrolledtrial
AT romeroenrique anewgenerationultralongactingbasalinsulinwithabolusboostcomparedwithinsulinglargineininsulinnaivepeoplewithtype2diabetesarandomizedcontrolledtrial
AT mersebachhenriette anewgenerationultralongactingbasalinsulinwithabolusboostcomparedwithinsulinglargineininsulinnaivepeoplewithtype2diabetesarandomizedcontrolledtrial
AT dykielpatrik anewgenerationultralongactingbasalinsulinwithabolusboostcomparedwithinsulinglargineininsulinnaivepeoplewithtype2diabetesarandomizedcontrolledtrial
AT jorderolf anewgenerationultralongactingbasalinsulinwithabolusboostcomparedwithinsulinglargineininsulinnaivepeoplewithtype2diabetesarandomizedcontrolledtrial
AT heisetim newgenerationultralongactingbasalinsulinwithabolusboostcomparedwithinsulinglargineininsulinnaivepeoplewithtype2diabetesarandomizedcontrolledtrial
AT tackceesj newgenerationultralongactingbasalinsulinwithabolusboostcomparedwithinsulinglargineininsulinnaivepeoplewithtype2diabetesarandomizedcontrolledtrial
AT cuddihyrobert newgenerationultralongactingbasalinsulinwithabolusboostcomparedwithinsulinglargineininsulinnaivepeoplewithtype2diabetesarandomizedcontrolledtrial
AT davidsonjaime newgenerationultralongactingbasalinsulinwithabolusboostcomparedwithinsulinglargineininsulinnaivepeoplewithtype2diabetesarandomizedcontrolledtrial
AT gouetdidier newgenerationultralongactingbasalinsulinwithabolusboostcomparedwithinsulinglargineininsulinnaivepeoplewithtype2diabetesarandomizedcontrolledtrial
AT lieblandreas newgenerationultralongactingbasalinsulinwithabolusboostcomparedwithinsulinglargineininsulinnaivepeoplewithtype2diabetesarandomizedcontrolledtrial
AT romeroenrique newgenerationultralongactingbasalinsulinwithabolusboostcomparedwithinsulinglargineininsulinnaivepeoplewithtype2diabetesarandomizedcontrolledtrial
AT mersebachhenriette newgenerationultralongactingbasalinsulinwithabolusboostcomparedwithinsulinglargineininsulinnaivepeoplewithtype2diabetesarandomizedcontrolledtrial
AT dykielpatrik newgenerationultralongactingbasalinsulinwithabolusboostcomparedwithinsulinglargineininsulinnaivepeoplewithtype2diabetesarandomizedcontrolledtrial
AT jorderolf newgenerationultralongactingbasalinsulinwithabolusboostcomparedwithinsulinglargineininsulinnaivepeoplewithtype2diabetesarandomizedcontrolledtrial